Skip to main content

Table 5 Discounted and undiscounted incremental lifetime cost-effectiveness ratio’s, overall and by gender

From: Cost-effectiveness of enzyme replacement therapy for Fabry disease

  Discount rate at 1.5% for effects and 4% for costs Discount rate at 0% for effects and costs
ALL   
Incremental costs per extra year free of end-organ damage €3,318,239 €6,560,885
Incremental costs per QALY gained €3,282,252 €6,065,529
MALES   
Incremental costs per extra year free of end-organ damage €2,982,022 €5,917,091
Incremental costs per QALY gained €2,947,380 €5,451,797
FEMALES   
Incremental costs per extra year free of end-organ damage €3,797,767 €7,527,013
Incremental costs per QALY gained €3,742,702 €6,955,612